Best Blue Chip Stocks this April 2026 in the UK

Glencore stands out as a top-rated stock idea for 2026, reflecting its strong positioning in the mining and commodities sector. With a solid dividend yield of 2.17% and impressive returns of 83.55% over the past year, it presents an attractive opportunity for investors seeking reliable income and growth potential. Analysts have set a 12-month price target of $9.30, underscoring the company's strong market prospects and ongoing upgrades from Credit Suisse.

Rolls-Royce Holdings has been recognized among Europe's top 25 stock picks for outperformance in 2026, highlighting its strategy in the aerospace and defense sectors. With a remarkable 1-year return of 48.80% and an impressive 5-year return of 923.77%, this company appeals to investors seeking growth. Additionally, it boasts a dividend yield of 0.82%, supported by strong ratings from analysts, including upgrades from Redburn Partners.

Rolls-Royce (RYCEY) reported a 40% increase in annual profit, driven by strong demand for its commercial aircraft engines and growth in its data center segment.

RELX stands out as a top-rated information and analytics company, recommended for strong performance among FTSE 100 blue-chips by analysts for 2026. With a dividend yield of 2.84%, it appeals to investors seeking reliable income from financially healthy firms, despite a recent 1-year return of -34.73%. Notably, Goldman Sachs and Citigroup have upgraded their ratings to "Buy," indicating growing confidence in its long-term potential.

RLX Technology has a consensus rating of 'Strong Buy' from 4 analysts.

Rent the Runway, Inc. (RENT) is currently trading near the bottom of its 52-week range at $4.47, reflecting a 1.32% drop of $0.06 since the last market close.

Analysts project an average 12-month price target of 0.8000 CAD for Defiance Silver (DEF), with both the high and low estimates also at 0.8 CAD.

Rentokil Initial is a pest control and facilities services company poised for strong performance through 2026, backed by projected earnings growth of 26.5% per annum. With a current dividend yield of 2.00% and a notable 1-year return of 30.1%, it presents an attractive option for investors seeking reliable income. The stock has garnered a positive outlook from analysts, with five buy ratings indicating confidence in its future growth trajectory.

Seven Wall Street analysts have rated Rentokil Initial, with 5 buy ratings, 1 hold, and 1 sell. The consensus recommendation is a 'moderate buy.'

Rentokil Initial is expected to grow earnings by 26.5% and revenue by 4.5% annually, with an EPS growth forecast of 27% and a return on equity of 14.1% in three years.

Rentokil Initial typically pays dividends twice a year, with amounts determined by the directors, and can be received in cash or reinvested to purchase more shares.

HSBC offers an attractive dividend yield of 4.77% alongside impressive historical performance, boasting a 36.49% return over the past year and a remarkable 174.78% over the last five years. With a median 12-month price target of $52.00 and a Zacks Rank of #2 (Buy), the stock is well-positioned for continued growth, although recent analyst ratings show some divergence, indicating a mix of optimism and caution among experts. Overall, HSBC stands out as a compelling investment opportunity for those seeking both income and capital appreciation.

HSBC has a Zacks Rank of #2 (Buy), indicating it is expected to outperform the market in the near term.

HSBC is currently considered undervalued by 45.5% according to our Excess Returns analysis.

Diageo stands out as a top 10 dividend stock and is recommended as a blue-chip investment for those considering an ISA, even amidst recent challenges in the drinks sector due to rising inflation. With strong analyst ratings of B, it remains a compelling choice for investors seeking reliable income from a financially healthy company. Despite its current struggles, Diageo's reputation for consistent payouts positions it well for long-term stability.

Diageo is facing challenges due to a downturn in the drinks sector, influenced by higher inflation that has led consumers to choose cheaper products.

As of December 31, 2025, Berkshire Hathaway holds 227,750 shares of Diageo, valued at $19.65 million, representing 0.01% of their portfolio.

British American Tobacco stands out as a top-rated dividend stock, boasting a noteworthy dividend yield of 5.73% and a solid track record of progressive payouts. With a one-year return of 41.44% and a five-year return of 47.08%, it represents an attractive option for investors seeking reliable income from financially healthy companies. Analysts currently rate the stock with a median price target of $40.00, suggesting a consensus for a moderate buy despite concerns about its valuation.

As of March 24, 2026, British American Tobacco p.l.c. is considered expensive based on valuation metrics.

Wall Street analysts recommend a 'moderate buy' for BTI shares, with a predicted downside of approximately 12.85% over the next 12 months.

British American Tobacco aims to have 50 million consumers of its Smokeless Products by 2030, and currently has 34.1 million consumers.

The price target for BTI ranges from $40.50 to $69.00, with an average target suggesting a 4.37% increase from the last closing price of $58.09.

AstraZeneca stands out as a highly regarded pharmaceutical company, recommended for blue-chip investments, particularly for those considering new ISA options. Analysts anticipate solid outperformance by 2026, backed by a consensus rating of Moderate Buy, which reflects 12 buy ratings compared to just 1 sell. Currently, AstraZeneca is trading near the top of its 52-week range, indicating strong performance and market confidence.

AstraZeneca PLC has a consensus rating of 'Moderate Buy' from analysts, with 12 buy ratings, 2 hold ratings, and 1 sell rating. The average 12-month price target is 15,989.52.

AstraZeneca is trading near its 52-week high and above its 200-day moving average, with a recent increase of $0.51, or 0.27%.

AstraZeneca shares fell after Deutsche Bank downgraded the stock to 'Sell' and set a lower target price of 10,500p, resulting in a drop of 236p to 12,408p.

The market values AstraZeneca highly due to the strength and quality of its oncology franchise.

With a forward dividend yield of 9.14%, Legal & General Group stands out as an attractive option for investors seeking reliable passive income. Although it has experienced a slight one-year return of -0.31% and a more significant decline of 17.78% over five years, its ability to generate substantial tax-free income from an £11,100 ISA investment remains appealing. Analysts rate it a C, suggesting a cautious approach to its potential.

First Majestic Silver has a Strong Buy rating, with a 71.05% probability of outperforming the market in the next three months.

GN Store Nord has a consensus rating of 'Hold' from six analysts, with recent ratings ranging from 'strong sell' to 'overweight'.

Ganfeng Lithium A has a consensus rating of 'Buy', with 14 analysts recommending a buy, 3 suggesting a sell, and 4 advising to hold.

GLP has a Zacks Rank of #2 (Buy) and a P/E ratio of 14.79, which is below the industry average of 15.19.